It would not make sense that Chris would not want Kirk's involvement. Kirk could have had a representative on the board, but never made the move. Kirk's warrants get repriced when there is a SO, I am not sure what happens when the shares are sold to Lincoln. Kirk's investment continues to put a premium on SNGX's PPS. To sell 3.3 million shares in such a lightly traded stock would be devastating to the PPS. If he sold the price would spiral down so low, it wouldn't be hardly worth it to him to sell. Moreover, if he sold, he would be admitting that he made a mistake which would be a blow to his ego and his reputation with investors. Better to let it sit there forever, if needed. As I said all along, his silence and no actions speak volumes.
Chris' actions to keep all his employees paychecks coming aligns with his job to keep SNGX solvent. Is he the best person for the job? No. Should he be replaced and restore some credibility with investors? Yes He is not committing fraud as some accuse him of. He can hide behind the safe harbor clauses that accompany anything that he says or is in writing.
SNGX is a development stage company that has a high element of risk. Higher than other companies in the same shoes? Well, that is what you the investor has to decide.
WASHINGTON–Mosquitoes carrying the dangerous Zika virus are expected to begin infecting Americans within the U.S. in the next “month or so,” the government’s top infectious disease expert said Sunday, as officials race to prevent a widespread outbreak of the virus that is believed linked to birth defects.
Ring...ring ...ring...Hello, this is Oxitec, how can I help you?......
Thanks! I am not sure how they gather this information or how often it is updated, since the institutions only report their holdings to the SEC on a quarter basis. There can be double counts even when using the SEC data reported in the 13F filings, so it is possible the same thing could happen here. The only thing that matters is NRZ is higher! GL!
I do not know how many other readers are smirking after reading your post, but I find it to be utterly ridiculous for you to think this. Kirk's investment gave SNGX a lot of credibility at the time and the stock moved up accordingly. I hate to think where PPS would be today, if Kirk's investment was not known by investors.
I am not sure what point your data is referring to, but typically the data is reported on a quarterly basis. I get my information from the NASDAQ site. Based upon the data reported by institutions as of March 31, Institutional holdings fell to 64%. PPS on that day was $11.63. By the time we the retailers get this information, it is already stale. We all know that hedge funds have been selling shares in their holdings due to redemptions. I am sure NRZ was also impacted, but as we also know NRZ is much higher today. We'll see who the buyers have been.
No investor conferences, no posters, or abstracts at medical conferences, no new analysts, no earnings calls, no investor day...we chillin. Pssst, we're negotiating deals, big deals, but I've said too much already.
Nothing! They do not have a larger enough staff to bother with something like this. Look where we ended for the day.
I think the chance of the accelerated approval will be decided in Q4, but this data looks more of the same to me.
Kirk bought 3,333,333 shares of Common Stock for cash and received warrants to purchase 2,500,000 shares of Common Stock. The remaining 1 million shares of stock was received by XON when the ECC agreement with SNGX was set up in 2013. As we know, the ECC agreement is on a permanent hold.
Paolo Cavazza, Marco M. Brughera and Gregg A. Lapointe all came from Sigma-Tau Pharmaceuticals, Inc. The latter is related to Orbec that failed as a P3 study. Additionally, Gregg A. Lapointe is a director of Sciclone Pharma, the company that is in the wings to partner with SNGX if SGX942 ever develops into something.
So, as you can see Chris is not going anywhere, no matter what your feelings are about him.
Dorothy, you're not in Kansas anymore. You can stomp your feet and hold your breath, but there is no catalyst to oust Chris from his perch. The board members are a bunch of bench sitters, happy to collect there BOD fees. You're kidding yourself, if you're thinking anything different. Sorry for a reality check. Anyone who thinks that Zeldis would ever consider taking the CEO role and step down from his cushy job at his age is dreaming.
If 301 had any hope, it would not have been sold to a company without cash resources, no less for 90% stock. Look where PPS is since the purchase. SGX942 was purchased from a failed company. Same story over and over again. ORBEC trials follows the definition of insanity - doing the same thing over and over again, but expecting different results. The only thing SNGX has going for it is investor greed. Investors believing they see something that no one else sees and therefore buys SNGX because it looks cheap. Admittedly, It does look cheap, but there is a reason. THe defense business has hope, or at least brings in income but SNGX wastes its resources elsewhere. Sorry, it had to be said.
We'll see. Just becuse he was not on the call and got brownie points does not mean his questions were not answered at some point. You will never know whether he listened to the call. Just because one does not like his downgrade, one cannot poo poo it away. NRZ needs to continue to perform and do deals. That is all that matters. Most of these guys analyze so many companies, they are behind the curve. Q2 results will be here before you know it. Bob can post the same old tired update of the analyst opinions and it looks nice, but consistent earnings and accretive deals is what will win the day. A deal with OCN is on the horizon, IMO. GL!
Looks like what we already know. What am I missing? Thanks
So you think when a company is in a quiet, or blackout period this information would be shared with "key institutional ownership"? Wouldn't that defeat the purpose of a quiet period, if you told parties of pending news that did not have to know? And what makes them "key"? You're a funny guy.
Don't you think that the Phase 3 PEG trial began quickly? The FDA must be VERY SATISFIED with the data presented. Spit out your posts as fast as you can, but it will not change the facts. PEGPH20 IS making a big difference in extending the lives of these unfortunate patients.
Griffin is not an objective analyst company for XON, IMO. Any firm where you can get their analysis without being a client is suspect to me. Some of Griffin's analyses for companies is not accessible to the public, but XON is. JT Marlin - Who? Google them and see what stories come up.
Merger - We've said that for years and it hasn't happened.
I think there is little chance that the HCP spin off would buy SNR, since Wes would not sell it willingly and lose the management fee, imo.
That is what happens when there is a merger, but that does NOT make him NOT a good hire for XON. He is 55 years old, so at his level he could have also chosen to retire and didn't. He is a seasoned exec and I am sure he did his DD before accepting a position at a development stage company which could be viewed by some as a step down. That is par tof the reason it s good news for shareholders. Is validates our convictions in light of all the litigation and spotlight accusations.